{"id":"nadroparin-calcium-warfarin-sequential-anticoagulation","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Heparin-induced thrombocytopenia (HIT)"},{"rate":null,"effect":"Skin necrosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nadroparin calcium is a low-molecular-weight heparin that inhibits Factor Xa and thrombin, providing rapid anticoagulation. Warfarin is a vitamin K antagonist that inhibits synthesis of vitamin K-dependent clotting factors (II, VII, IX, X), providing sustained anticoagulation. The sequential approach uses nadroparin for initial rapid anticoagulation, then transitions to warfarin for long-term maintenance therapy.","oneSentence":"A sequential anticoagulation regimen combining nadroparin calcium (low-molecular-weight heparin) followed by warfarin to prevent thromboembolism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:56:31.778Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Venous thromboembolism prevention and treatment"},{"name":"Atrial fibrillation with thromboembolism risk"}]},"trialDetails":[{"nctId":"NCT04976543","phase":"PHASE4","title":"Safety of Anticoagulant Therapy After Endoscopic Treatment","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2020-02-01","conditions":"Cirrhosis, Portal Vein Thrombosis, Esophageal and Gastric Varices","enrollment":86},{"nctId":"NCT04173429","phase":"PHASE4","title":"Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2017-01-01","conditions":"Liver Cirrhosis, Portal Vein Thrombosis","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["anticoagulation"],"phase":"marketed","status":"active","brandName":"nadroparin calcium-warfarin sequential anticoagulation","genericName":"nadroparin calcium-warfarin sequential anticoagulation","companyName":"Qilu Hospital of Shandong University","companyId":"qilu-hospital-of-shandong-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A sequential anticoagulation regimen combining nadroparin calcium (low-molecular-weight heparin) followed by warfarin to prevent thromboembolism. Used for Venous thromboembolism prevention and treatment, Atrial fibrillation with thromboembolism risk.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}